Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation
dc.contributor.author | Martin, T. | en_US |
dc.contributor.author | Sharma, M. | en_US |
dc.contributor.author | Damon, L. | en_US |
dc.contributor.author | Kaplan, L. | en_US |
dc.contributor.author | Guglielmo, B. J. | en_US |
dc.contributor.author | Working, M. | en_US |
dc.contributor.author | O'Malley, R. | en_US |
dc.contributor.author | Hwang, J. | en_US |
dc.contributor.author | Linker, C. | en_US |
dc.date.accessioned | 2010-06-01T20:14:21Z | |
dc.date.available | 2010-06-01T20:14:21Z | |
dc.date.issued | 2010-02 | en_US |
dc.identifier.citation | Martin, T.; Sharma, M.; Damon, L.; Kaplan, L.; Guglielmo, B.J.; Working, M.; O'Malley, R.; Hwang, J.; Linker, C. (2010). "Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation." Transplant Infectious Disease 12(1): 45-50. <http://hdl.handle.net/2027.42/73360> | en_US |
dc.identifier.issn | 1398-2273 | en_US |
dc.identifier.issn | 1399-3062 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/73360 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19793068&dopt=citation | en_US |
dc.description.abstract | Seventy-two patients undergoing allogeneic transplantation were treated with voriconazole (VOR) as antifungal prophylaxis starting from day −2 of transplantation and continuing until withdrawal of immunosuppression. Patients were assessed for safety and the incidence of definite, probable, or possible fungal infection throughout transplantation was evaluated. VOR was well tolerated. Only 14% of patients required interruption of VOR therapy because of toxicity: liver toxicity (8%), cardiac Q –T interval prolongation (1%), or other side effects (5%). In the early post-transplant period (<120 days), only 2 patients developed invasive fungal infection: 1 mucormycosis infection and 1 disseminated Aspergillus infection. In the late post-transplant period (>120 days), no patients developed probable or definite fungal infection while receiving VOR. No Candida infections were seen in either period. These data suggest that fungal prophylaxis with VOR following allogeneic transplantation is safe and effective. | en_US |
dc.format.extent | 192800 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Inc | en_US |
dc.rights | © 2010 John Wiley & Sons A/S | en_US |
dc.subject.other | Voriconazole | en_US |
dc.subject.other | Mucormycosis | en_US |
dc.subject.other | Aspergillus | en_US |
dc.subject.other | Allogeneic | en_US |
dc.subject.other | Stem Cell Transplant | en_US |
dc.subject.other | Fungal Infections | en_US |
dc.title | Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbsecondlevel | Microbiology and Immunology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | Division of Hematology/Oncology, University of California—San Francisco, San Francisco, California, USA | en_US |
dc.contributor.affiliationother | Division of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA | en_US |
dc.contributor.affiliationother | Department of Clinical Pharmacy, School of Pharmacy, University of California—San Francisco, San Francisco, California, USA | en_US |
dc.contributor.affiliationother | Biostatistics Core Facility, University of California—San Francisco, San Francisco, California, USA | en_US |
dc.identifier.pmid | 19793068 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/73360/1/j.1399-3062.2009.00455.x.pdf | |
dc.identifier.doi | 10.1111/j.1399-3062.2009.00455.x | en_US |
dc.identifier.source | Transplant Infectious Disease | en_US |
dc.identifier.citedreference | Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326 ( 13 ): 845 – 851. | en_US |
dc.identifier.citedreference | Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96 ( 6 ): 2055 – 2061. | en_US |
dc.identifier.citedreference | Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study. J Infect Dis 1995; 171 ( 6 ): 1545 – 1552. | en_US |
dc.identifier.citedreference | Ullmann A, Lipton J, Vesole D, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356 (4): 335 – 347. | en_US |
dc.identifier.citedreference | Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347 ( 6 ): 408 – 415. | en_US |
dc.identifier.citedreference | Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34 ( 1 ): 7 – 14. | en_US |
dc.identifier.citedreference | Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia 2006; 162 ( 1 ): 1 – 15. | en_US |
dc.identifier.citedreference | Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 75 ( 6 ): 1459 – 1466. | en_US |
dc.identifier.citedreference | Fukuda T, Hackman RC, Guthrie KA, et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003; 102 ( 8 ): 2777 – 2785. | en_US |
dc.identifier.citedreference | Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100 ( 13 ): 4358 – 4366. | en_US |
dc.identifier.citedreference | Siwek GT, Pfaller MA, Polgreen PM, et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis 2006; 55 ( 3 ): 209 – 212. | en_US |
dc.identifier.citedreference | Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007; 40 ( 5 ): 451 – 456. | en_US |
dc.identifier.citedreference | Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350 ( 9 ): 950 – 952. | en_US |
dc.identifier.citedreference | Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39 ( 4 ): 584 – 587. | en_US |
dc.identifier.citedreference | Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39 ( 7 ): 425 – 429. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.